12月16日,，在線發(fā)表在Cancer雜志上一項對新西蘭中年男性的研究"Statin use and fatal prostate cancer: A matched case-control study"表明,，他汀類藥物治療與前列腺癌造成的死亡率下降具有相關(guān)性。人們服用那些藥物可能是為了心臟,，但是同時對前列腺也有好處,。
研究人員Stephen Marcella博士等收集了380名死于前列腺病人的醫(yī)療記錄，以及380名年齡和種族相匹配的對照組的記錄,。大多數(shù)男性是白種人,，平均60多歲，接近25%的病人服用過一種他汀類藥物,。
研究人員發(fā)現(xiàn),，死于前列腺癌的病人比對照組病人服用他汀類藥物的可能性減半,。調(diào)整了體重、并發(fā)癥和藥物后,，患致命性前列腺癌的男性服用他汀類藥物的可能性降低63%,。
但是，Marcella博士補充說,，我不會告訴一個人說,，如果他沒有心臟病的風(fēng)險，沒有高血壓的風(fēng)險,，讓他們?nèi)シ盟☆愃幬镏皇菫榱祟A(yù)防致命性前列腺癌,。
Marcella博士的團隊還不確定是否服用他汀類藥物時間長一些，或者服用藥物早一些,，會更加有益,。他們也不能確定病人是在診斷出侵略性癌癥之前還是之后服用他汀類藥物。
但是他們確實發(fā)現(xiàn),，較新的高效力的他汀類藥物與較低的致命性前列腺癌風(fēng)險有關(guān),，低效力藥物沒有這種作用。表明是某些藥物本身具有降低死于前列腺癌的風(fēng)險,。
杜克大學(xué)醫(yī)學(xué)中心的Stephen Freedland博士講到,，他汀類藥物預(yù)防致命性前列腺癌可能是通過降膽固醇作用實現(xiàn)的。膽固醇是癌細(xì)胞的關(guān)鍵營養(yǎng)素,，所以降低膽固醇水平可以預(yù)防癌癥的發(fā)展,。但是也有可能他汀類藥物根本不具有預(yù)防某些癌癥的功能，可能是因為服用他汀類藥物的人群改變飲食或者開始鍛煉,，這些因素導(dǎo)致致命性癌癥的風(fēng)險降低,。（生物谷bioon.com）
doi:10.1002/cncr.26720
PMC:
PMID:
Statin use and fatal prostate cancer: A matched case-control study
Marcella SW, David A, Ohman-Strickland PA, Carson J, Rhoads GG.
BACKGROUND:
Statins are some of the most commonly prescribed medications in medical practice, and prostate cancer is the most common malignancy among men. Although there has been no consistent evidence that statins affect cancer incidence, including prostate cancer, several reports suggest they may decrease the rate of advanced prostate cancer. However, no study to date has specifically examined statin use and prostate cancer mortality. The authors conducted this population-based case-control investigation to examine this association.
METHODS:
This was a matched case-control study. Cases were residents of New Jersey ages 55 to 79 years who died from prostate cancer between 1997 and 2000. The cases were matched individually to population-based controls by 5-year age group and race. Medication data were obtained identically for cases and controls from blinded medical chart review. Conditional logistic regression was used to adjust for confounders.
RESULTS:
In total, 718 cases were identified, and cooperation was obtained from 77% of their spouses (N = 553). After a review of medical records, 387 men were eligible, and 380 were matched to a control. The unadjusted odds ratio was 0.49 (95% confidence interval, 0.34-0.70) and decreased to 0.37 (P < .0001) after adjusting for education, waist size, body mass index, comorbidities, and antihypertensive medication. There was little difference between lipophilic and hydrophilic statins, but more risk reduction was noted for high-potency statins (73%; P < .0001) compared with low-potency statins (31%; P = .32).
CONCLUSIONS:
Statin use was associated with substantial protection against prostate cancer death, adding to the epidemiologic evidence for an inhibitory effect on prostate cancer. Cancer 2012;. ? 2011 American Cancer Society.
